Tirzide 5 mg (Tirzepatide INN)

Dual GIP & GLP-1 Receptor Agonist for Advanced Type 2 Diabetes Control

💊 Pharmacology:

Tirzepatide is a novel dual incretin receptor agonist that activates:

• Glucose-dependent insulinotropic polypeptide (GIP) receptors

• Glucagon-like peptide-1 (GLP-1) receptors

This dual action results in:

• Enhanced glucose-dependent insulin secretion

• Reduced glucagon release

• Delayed gastric emptying

• Increased satiety and appetite control

• Significant HbA1c reduction

• Clinically meaningful weight loss

The 5 mg strength is typically used after the initial 2.5 mg starting dose for improved glycemic response.

📌 Indications:

Tirzide® 5 mg is indicated for:

• Type 2 Diabetes Mellitus as an adjunct to diet and exercise

• Patients requiring additional glycemic control after initiation therapy

• May contribute to weight management in diabetic patients

Not indicated for:

• Type 1 Diabetes

• Diabetic ketoacidosis

💉 Dosage & Administration:

• Administered as a once-weekly subcutaneous injection

• Typically used after 4 weeks of 2.5 mg initiation dose

• Inject into abdomen, thigh, or upper arm

• Can be administered with or without food

• Dose adjustments should be made only under physician guidance

⚠️ Precautions & Warnings:

• Monitor blood glucose regularly

• Risk of gastrointestinal reactions (especially during dose escalation)

• Caution in patients with history of pancreatitis

• Monitor for hypoglycemia when used with insulin or sulfonylureas

• Not recommended in severe gastrointestinal disease

• Observe for signs of thyroid-related abnormalities

❌ Contraindications:

• Hypersensitivity to Tirzepatide or any component

• Personal or family history of medullary thyroid carcinoma (MTC)

• Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

🤰 Pregnancy & Lactation:

• Not recommended during pregnancy

• Breastfeeding should be avoided during therapy

• Effective contraception advised for women of childbearing age

⚕️ Side Effects:

Common side effects include:

• Nausea

• Vomiting

• Diarrhea

• Decreased appetite

• Constipation

• Injection site reactions

Less common but serious:

• Pancreatitis

• Severe hypoglycemia (when combined with insulin)

• Possible thyroid C-cell tumor risk (animal studies)

🧊 Storage Conditions:

• Store refrigerated at 2°C–8°C

• Do not freeze

• Protect from light

• Keep out of reach of children